ArticleArchives of rheumatology2025
Syndecan-1 as a Biomarker for Cardiovascular Risk in Patients with Behçet's Disease.
Article in Archives of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsThis study aimed to assess the potential of syndecan-1 levels as a biomarker for diagnosing cardiovascular diseases and atherosclerosis in patients with Behçet's disease. MATERIALS AND
methodsAfter estimating the required sample size, 56 patients with Behçet's disease and 56 age- and sex-matched controls were enrolled in the study. Carotid intima-media thickness (cIMT) was measured by a single radiologist using an appropriate technique. Syndecan-1 levels were determined with an Syndecan-1 human ELISA kit (CLOUD CLONE, USCN). The test system showed a correlation coefficient of 0.99 between expected and actual values, with a detection limit of around 0.01 ng/mL. The intra-assay coefficient of variation (CV) was under 10%, and the inter-assay CV was under 12%.
resultsThe data obtained from the study showed that syndecan-1 levels (P < .002) and cIMT measurements (P < .015) were significantly higher in patients with Behçet's disease compared to the healthy control group. Additionally, correlation analysis revealed a significant negative relationship between syndecan-1 levels and cIMT. In a stepwise multiple regression analysis, a strong independent relationship was found between cIMT and age (beta [β] = 0.474, P < .001), syndecan-1 (β = 0.302, P = .007), and low-density lipoprotein (β = 0.219, P = .050).
conclusionSyndecan-1 levels were higher in patients with Behçet's disease compared to controls, and increased syndecan-1 may slow the progression of subclinical atherosclerosis. This study is a preliminary investigation. Further detailed studies are needed. Cite this article as: Kadıyoran C, Diydem Yılmaz P, Hakan Göktepe M, et al. Syndecan-1 as a biomarker for cardiovascular risk in patients with Behçet's disease. Arch Rheumatol. 2025;40(4):435-442.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.